var data={"title":"Pathogenesis of type 2 diabetes mellitus","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pathogenesis of type 2 diabetes mellitus</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/contributors\" class=\"contributor contributor_credentials\">David K McCulloch, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/contributors\" class=\"contributor contributor_credentials\">R Paul Robertson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/contributors\" class=\"contributor contributor_credentials\">David M Nathan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/contributors\" class=\"contributor contributor_credentials\">Jean E Mulder, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 17, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Type 2 diabetes mellitus is characterized by hyperglycemia, insulin resistance, and relative impairment in insulin secretion. It is a common disorder with a prevalence that rises markedly with increasing degrees of obesity (<a href=\"image.htm?imageKey=ENDO%2F51105\" class=\"graphic graphic_figure graphicRef51105 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/1\" class=\"abstract_t\">1</a>]. The prevalence of type 2 diabetes has risen alarmingly in the past decade [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/2\" class=\"abstract_t\">2</a>], in large part linked to the trends in obesity and sedentary lifestyle [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PATHOPHYSIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Understanding the pathogenesis of type 2 diabetes is complicated by several factors [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/4\" class=\"abstract_t\">4</a>]. Patients present with a combination of varying degrees of insulin resistance and relative insulin deficiency, and it is likely that both contribute to type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/5-7\" class=\"abstract_t\">5-7</a>]. Furthermore, each of the clinical features can arise through genetic or environmental influences, making it difficult to determine the exact cause in an individual patient. Moreover, hyperglycemia itself can impair pancreatic beta-cell function and exacerbate insulin resistance, leading to a vicious cycle of hyperglycemia causing a worsening metabolic state [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/8\" class=\"abstract_t\">8</a>].</p><p>Type 2 diabetes is often accompanied by other conditions, including hypertension, high serum low-density lipoprotein (LDL) cholesterol concentrations, and low serum high-density lipoprotein (HDL) cholesterol concentrations that, like type 2 diabetes, increase cardiovascular risk. This constellation of clinical conditions is referred to as the metabolic syndrome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/9\" class=\"abstract_t\">9</a>]. Hyperinsulinemia occurring in response to insulin resistance may play an important role in the genesis of these abnormalities. Increased free fatty acid levels, inflammatory cytokines from fat, and oxidative factors have all been implicated in the pathogenesis of metabolic syndrome, type 2 diabetes, and their cardiovascular complications. (See <a href=\"topic.htm?path=the-metabolic-syndrome-insulin-resistance-syndrome-or-syndrome-x\" class=\"medical medical_review\">&quot;The metabolic syndrome (insulin resistance syndrome or syndrome X)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Impaired insulin secretion and insulin resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The relative importance of impaired insulin release and insulin resistance in the pathogenesis of type 2 diabetes has been evaluated in several studies [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/10-12\" class=\"abstract_t\">10-12</a>]. As an example, in a prospective study of over 6500 British civil servants without diabetes at baseline, 505 subjects were diagnosed with diabetes during 9.7 years (median) of follow-up [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/13\" class=\"abstract_t\">13</a>]. In those who developed diabetes compared with those who did not, there was a marked decrease in insulin sensitivity during the five years prior to diagnosis. Beta-cell function (insulin secretion) increased three to four years prior to diagnosis and then decreased until diagnosis. In addition, a seven-year prospective study of 714 nondiabetic Mexican-Americans suggested that decreased insulin secretion and insulin resistance were independent risk factors for type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/11\" class=\"abstract_t\">11</a>]. Among Pima Indians, in whom the frequency of diabetes is very high, the transition from normal glucose tolerance to impaired glucose tolerance to diabetes is characterized by concomitant decreases in insulin-stimulated glucose disposal and glucose-stimulated insulin secretion [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/12\" class=\"abstract_t\">12</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h3\">Insulin secretion</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Insulin secretion by beta cells requires glucose transport into the cell, which is, at least in part, mediated by the glucose transporter 2 (GLUT-2). A mouse model with a genetic alteration affecting GLUT-2 expression produced mice with glucose intolerance; similar changes in GLUT-2 could be induced in normal mice fed a high-fat diet [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/14\" class=\"abstract_t\">14</a>] and suggests a possible mechanism for the link between high-fat diet and the development of diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/15\" class=\"abstract_t\">15</a>].</p><p>Impaired insulin secretion has also been demonstrated to occur in mice lacking Abca1, a cellular cholesterol transporter [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/16\" class=\"abstract_t\">16</a>]. Mice with inactivation of Abca1 in beta cells have defective insulin secretion, impaired glucose tolerance but normal insulin sensitivity.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h3\">Insulin resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Insulin resistance may be the best predictor of type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/5,6\" class=\"abstract_t\">5,6</a>]. The vast majority of patients appear to have a genetic risk for type 2 diabetes (see <a href=\"#H8\" class=\"local\">'Genetic susceptibility'</a> below). It is possible, for example, that insulin resistance becomes more severe with increasing age and weight, thereby unmasking a concurrent defect in insulin secretion in susceptible subjects to cause impaired glucose tolerance and eventually overt hyperglycemia. In normal-weight, nondiabetic subjects at high risk for type 2 diabetes, both fasting and post-glucose hyperinsulinemia predict future weight gain, which in turn predisposes to hyperglycemia [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/17,18\" class=\"abstract_t\">17,18</a>]. Hyperglycemia itself may contribute to further progression by a toxic effect on beta cells, possibly by decreasing insulin gene expression [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/19\" class=\"abstract_t\">19</a>].</p><p>Insulin resistance may, at least in part, be related to substances secreted by adipocytes (&quot;adipokines,&quot; including leptin, adiponectin, tumor necrosis factor-alpha [TNFa], and resistin). (See <a href=\"#H20\" class=\"local\">'Factors released from adipose tissue'</a> below.)</p><p>The importance of genetic factors in the pathogenesis of type 2 diabetes is suggested by the observation that lean, normoglycemic offspring of parents with type 2 diabetes have reduced nonoxidative glucose metabolism associated with reduced muscle glycogen synthesis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/20\" class=\"abstract_t\">20</a>]. Thus, insulin resistance is present years before the onset of hyperglycemia. An increase in intracellular lipid content in muscle has been identified in these insulin-resistant offspring, suggesting that dysregulation of fatty acid metabolism may mediate the insulin resistance in these individuals. In one study, this dysregulation appeared to be due to an inherited defect in mitochondrial function [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/21\" class=\"abstract_t\">21</a>].</p><p>The importance of the combination of genetic and environmental factors is suggested by another study of nondiabetic offspring of two parents with type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/6\" class=\"abstract_t\">6</a>]. Their insulin sensitivity was similar to that of normal subjects with no first-degree relatives with type 2 diabetes at near ideal body weight; with increasing degrees of obesity, however, the progressive decrease in insulin sensitivity was much more pronounced in those with a family history of type 2 diabetes (<a href=\"image.htm?imageKey=ENDO%2F70645\" class=\"graphic graphic_figure graphicRef70645 \">figure 2</a>) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/6\" class=\"abstract_t\">6</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Impaired insulin processing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Insulin production in normal subjects involves cleavage of insulin from proinsulin; 10 to 15 percent of secreted insulin is proinsulin and its conversion intermediates. In contrast, the proportion of immunoreactive insulin that is proinsulin in type 2 diabetes is increased considerably in the basal state (&gt;40 percent) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/22\" class=\"abstract_t\">22</a>]. The difference between normal and diabetic subjects becomes even more pronounced after stimulation with arginine or <a href=\"topic.htm?path=glucagon-drug-information\" class=\"drug drug_general\">glucagon</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/23\" class=\"abstract_t\">23</a>]. The increase in proinsulin secretion persists after matching for degree of obesity, suggesting that it represents beta-cell dysfunction and not merely the response to the increased secretory demand imposed by the insulin resistance of obesity [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/23\" class=\"abstract_t\">23</a>]. These findings suggest that the processing of proinsulin to insulin in the beta cells is impaired in type 2 diabetes or that there is insufficient time for granules to mature properly so that they release more proinsulin.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Role of islet amyloid polypeptide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Islet amyloid polypeptide (amylin) is stored in insulin secretory granules in the pancreatic beta cells. It is cosecreted with insulin, resulting in serum concentrations approximately one-tenth those of insulin, and is present in increased amounts in the pancreas of many patients with type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/24\" class=\"abstract_t\">24</a>]. First-phase serum insulin and amylin concentrations are lower in patients with impaired glucose tolerance compared with patients with normal glucose tolerance, and the concentrations are very low in patients with type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/25\" class=\"abstract_t\">25</a>].</p><p>High concentrations of amylin decrease glucose uptake and inhibit endogenous insulin secretion, suggesting that amylin may be directly involved in the pathogenesis of type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/26\" class=\"abstract_t\">26</a>]. However, administration of physiologic amounts of amylin has no acute effect on insulin secretion or insulin action in humans [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/27\" class=\"abstract_t\">27</a>]. On the other hand, the administration of an amylin antagonist to rats results in a fall in blood glucose and an increase in insulin secretion, suggesting that amylin may tonically inhibit insulin secretion [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/28\" class=\"abstract_t\">28</a>].</p><p>Thus, it remains unclear whether amylin has a causative role in type 2 diabetes or is merely present in increased amounts as a consequence of the defect in insulin secretion [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/29\" class=\"abstract_t\">29</a>]. There is no apparent association between the amylin gene and type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/30\" class=\"abstract_t\">30</a>].</p><p><a href=\"topic.htm?path=pramlintide-drug-information\" class=\"drug drug_general\">Pramlintide</a> is a synthetic analog of human amylin that slows gastric emptying, reduces postprandial rises in blood glucose concentrations, and improves glycated hemoglobin (A1C) concentrations in patients with type 1 and type 2 diabetes when given subcutaneously. (See <a href=\"topic.htm?path=amylin-analogs-for-the-treatment-of-diabetes-mellitus\" class=\"medical medical_review\">&quot;Amylin analogs for the treatment of diabetes mellitus&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">GENETIC SUSCEPTIBILITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Type 2 diabetes most likely represents a complex interaction among many genes and environmental factors. Monogenic causes of type 2 diabetes represent only a small fraction of cases and commonly inherited polymorphisms individually contribute only small degrees of risk for, or protection from, diabetes (<a href=\"image.htm?imageKey=ENDO%2F61582\" class=\"graphic graphic_figure graphicRef61582 \">figure 3</a>). Most of the genetic risk for type 2 diabetes results from complex polygenic risk factors.</p><p>Observations that demonstrate a genetic influence on the development of type 2 diabetes include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The prevalence of type 2 diabetes varies remarkably among ethnic groups living in the same environment [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/31\" class=\"abstract_t\">31</a>]. Type 2 diabetes is two to six times more prevalent in African Americans, Native Americans, Pima Indians, and Hispanic Americans in the United States than in whites [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/32,33\" class=\"abstract_t\">32,33</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thirty-nine percent of patients with type 2 diabetes have at least one parent with the disease [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/34\" class=\"abstract_t\">34</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among monozygotic twin pairs with one affected twin, approximately 90 percent of unaffected twins eventually develop the disease [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/35\" class=\"abstract_t\">35</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>First-degree relatives of patients with type 2 diabetes frequently have impaired nonoxidative glucose metabolism (indicative of insulin resistance) long before they develop type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/36\" class=\"abstract_t\">36</a>]. In addition, they may have beta-cell dysfunction, as evidenced by decreases in insulin and amylin release in response to glucose stimulation [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/37\" class=\"abstract_t\">37</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The lifetime risk for a first-degree relative of a patient with type 2 diabetes is 5 to 10 times higher than that of age- and weight-matched subjects without a family history of diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/31\" class=\"abstract_t\">31</a>].</p><p/><p>Even among groups with increased genetic risk for diabetes, however, environmental factors play a major role in the development of diabetes. As an example, the prevalence of diabetes among Pima Indians in Mexico is less than one-fifth that in United States Pima Indians (6.9 versus 38 percent) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/38\" class=\"abstract_t\">38</a>].</p><p>The search for plausible candidate genes has focused upon genes coding for proteins that might be involved in pancreatic development, insulin synthesis, secretion, or action (<a href=\"image.htm?imageKey=ENDO%2F64684\" class=\"graphic graphic_table graphicRef64684 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/6\" class=\"abstract_t\">6</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Pancreatic development and beta-cell function</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Genome-wide association analysis has played an important role in identifying several new diabetes susceptibility loci. Some of these loci are in genes involved in pancreatic development and insulin synthesis. As an example, a genome-wide association study to find genetic loci associated with type 2 diabetes in a French population confirmed the known association with the transcription factor 7-like 2 gene (<em>TCF7L2</em>) (see <a href=\"#H11\" class=\"local\">'Transcription factor genes'</a> below) and identified four new loci associated with an increased risk of type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/39\" class=\"abstract_t\">39</a>]. These loci (<em>SLC30A8</em>, <em>HHEX</em><span class=\"nowrap\">/<em>IDE</em>,</span> and <em>KCNJ11</em>) are involved in beta-cell development and insulin synthesis and appear to contribute substantially to type 2 diabetes risk. The population attributable risk for the four new loci plus <em>TCF7L2</em> was 70 percent. The results of the original genome-wide association study were quickly confirmed by four independent studies in diverse populations [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/40-43\" class=\"abstract_t\">40-43</a>].</p><p>A meta-analysis of three genome-wide association studies found six new loci associated with diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/44\" class=\"abstract_t\">44</a>]. Some of the loci (<em>NOTCH 2</em>, <em>JAZF1</em>) may be involved in pancreatic beta-cell growth and development.</p><p>In subsequent genome-wide association studies, the following findings were noted:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A susceptibility locus in the <em>KCNQ1</em> gene was noted in Japanese individuals [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/45\" class=\"abstract_t\">45</a>]. The association was subsequently confirmed in samples from Singaporean, Danish, and Mexican populations [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/46,47\" class=\"abstract_t\">46,47</a>]. The <em>KCNQ1</em> gene encodes the alpha subunit of the slowly acting component of the outward-rectifying potassium channel (KvLQT1). Mutations in <em>KCNQ1</em> are responsible for a subset of long QT-interval syndromes (see <a href=\"topic.htm?path=genetics-of-congenital-and-acquired-long-qt-syndrome#H4\" class=\"medical medical_review\">&quot;Genetics of congenital and acquired long QT syndrome&quot;, section on 'LQT type 1'</a>). <em>KCNQ1</em> is also expressed in pancreatic islet cells and KCNQ1 risk alleles disrupt beta-cell function. Twelve new loci were noted in individuals of European descent, including a second independent signal at the KCNQ1 locus [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/48\" class=\"abstract_t\">48</a>]. The identified loci affected both beta-cell function and insulin action.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Common variants in <em>WFS1</em>, a gene involved in beta-cell survival, were associated with susceptibility to type 2 diabetes. Mutations in this gene also cause a rare syndrome, called Wolfram syndrome, characterized by diabetes insipidus, nonautoimmune diabetes mellitus, optic atrophy, and deafness. (See <a href=\"topic.htm?path=classification-of-diabetes-mellitus-and-genetic-diabetic-syndromes#H19\" class=\"medical medical_review\">&quot;Classification of diabetes mellitus and genetic diabetic syndromes&quot;, section on 'Wolfram syndrome'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Insulin release</span></p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">Transcription factor genes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>One gene variant, representing single nucleotide polymorphisms at one of two loci (rs7903146 and rs12255372) in the <em>TCF7L2</em> gene, was found to significantly increase risk for type 2 diabetes in a case control study of a population in Iceland [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/49\" class=\"abstract_t\">49</a>]. It was also shown to increase diabetic risk in two other populations, including in the United States where the gene variant is widely prevalent: 38 percent of the United States cohort studied were heterozygous and 7 percent homozygous for the variant allele. Compared with noncarriers, the relative risk for type 2 diabetes was 1.45 for heterozygotes and 2.41 for homozygotes. The population-attributable risk for diabetes for this gene is estimated at 21 percent.</p><p>Subsequent analysis for this variant gene in samples from participants (n = 3548) in the Diabetes Prevention Program (DPP trial) found that homozygotes for the variant <em>TCF7L2</em> gene were more likely to progress from impaired glucose tolerance to diabetes over three years than those without the variant gene (HR 1.55, 95% CI 1.20-2.01) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/50\" class=\"abstract_t\">50</a>]. The impact was strongest in the placebo DPP group where the incidence of diabetes per 100 person-years for the homozygous variant genotype at rs7903146 compared with heterozygous and nonvariant genotypes was 18.5, 10.7, and 10.8, respectively. This variant genotype predisposing to type 2 diabetes is associated with decreased insulin secretion from the beta cell in response to oral and intravenous glucose [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/51\" class=\"abstract_t\">51</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h3\">MODY2 and MODY4</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Maturity onset diabetes of the young (MODY) is a rare cause of type 2 diabetes that has autosomal dominant transmission and features of both impaired insulin secretion and insulin resistance. One form, MODY2, appears to be due to mutations in the glucokinase gene on chromosome 7 [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/52\" class=\"abstract_t\">52</a>]. Markers in this region have been linked to type 2 diabetes in American blacks [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/53\" class=\"abstract_t\">53</a>] and some other ethnic groups but not in whites [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/54\" class=\"abstract_t\">54</a>]. Glucokinase, which phosphorylates glucose to glucose-6-phosphate, probably acts as the glucose sensor within pancreatic beta cells, and therefore, glucokinase defects likely result in decreased insulin secretion. (See <a href=\"topic.htm?path=classification-of-diabetes-mellitus-and-genetic-diabetic-syndromes#H9\" class=\"medical medical_review\">&quot;Classification of diabetes mellitus and genetic diabetic syndromes&quot;, section on 'Maturity onset diabetes of the young'</a>.)</p><p>Another form of MODY (MODY4) is associated with mutations in insulin promoter factor-1 (<em>IPF-1</em><span class=\"nowrap\">/<em>PDX-1</em>),</span> a pancreatic beta-cell transcription factor [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/55\" class=\"abstract_t\">55</a>]. These mutations result in decreased insulin secretion in response to glucose due to reduced binding of the protein to the insulin gene promoter [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/55,56\" class=\"abstract_t\">55,56</a>] and perhaps by altering fibroblast growth factor signaling in beta cells [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/57\" class=\"abstract_t\">57</a>]. Less severe mutations in <em><span class=\"nowrap\">IPF-1/PDX-1</em></span> may predispose to late-onset type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/56,58\" class=\"abstract_t\">56,58</a>]. (See <a href=\"topic.htm?path=classification-of-diabetes-mellitus-and-genetic-diabetic-syndromes#H9\" class=\"medical medical_review\">&quot;Classification of diabetes mellitus and genetic diabetic syndromes&quot;, section on 'Maturity onset diabetes of the young'</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h3\">Other</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several other genes that might affect insulin secretion, including the insulin gene and the genes for amylin and glucose transporters, have not been found to have any relationship to type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/6,30\" class=\"abstract_t\">6,30</a>]. On the other hand, a polymorphism in the human alpha adrenergic receptor gene (<em>ADRA2A</em>) was associated with reduced insulin secretion [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/59,60\" class=\"abstract_t\">59,60</a>]. In addition, a mutation in mitochondrial DNA has been associated with a rare subtype of type 2 diabetes that has been called maternally inherited diabetes and deafness; insulin secretion is impaired via an uncertain mechanism in this disorder. (See <a href=\"topic.htm?path=classification-of-diabetes-mellitus-and-genetic-diabetic-syndromes#H18\" class=\"medical medical_review\">&quot;Classification of diabetes mellitus and genetic diabetic syndromes&quot;, section on 'Genetic defects in mitochondrial DNA'</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Insulin action</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Insulin exerts its effects by first binding to a specific insulin receptor that is present on many cells throughout the body. The insulin receptor is a large transmembrane protein composed of two extracellular alpha subunits and two transmembrane and intracellular beta subunits that have intrinsic tyrosine kinase activity. When insulin binds to the extracellular portion of the receptor, the tyrosine kinase is activated, initiating a sequence of intracellular responses mediated in part by insulin receptor substrates [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/61,62\" class=\"abstract_t\">61,62</a>].</p><p>Several genetic syndromes of severe insulin resistance have been identified, many of which are associated with point mutations of the insulin receptor gene [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/61\" class=\"abstract_t\">61</a>]. These patients have marked hyperinsulinemia and sometimes other abnormalities, such as acanthosis nigricans and hyperandrogenism. However, as noted above, impaired glucose tolerance or overt diabetes only occurs in humans or in animals if compensatory increases in insulin secretion are inadequate [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/61,63,64\" class=\"abstract_t\">61,63,64</a>].</p><p>None of the syndromes associated with an insulin receptor defect plays an important role in the common forms of type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/6\" class=\"abstract_t\">6</a>]. Thus, the decrease in insulin responsiveness in type 2 diabetes is probably due to a postreceptor defect, presumably affecting one of the intracellular enzymes involved in glucose metabolism. In animals, for example, the gene for glycogen synthase (which promotes the conversion of glucose-6-phosphate to glycogen) (<a href=\"image.htm?imageKey=ENDO%2F68962\" class=\"graphic graphic_figure graphicRef68962 \">figure 4</a>) is involved in the susceptibility to diet-induced hyperglycemia [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/65\" class=\"abstract_t\">65</a>].</p><p>This observation may be relevant to humans because impaired glycogen synthesis is responsible for the early insulin resistance in nondiabetic, first-degree relatives of patients with type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/5,36\" class=\"abstract_t\">5,36</a>], and an association has been noted between a polymorphism of the glycogen synthase gene and the presence of diabetes in a subgroup of patients with a strong family history of type 2 diabetes, hypertension, and marked insulin resistance [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/66\" class=\"abstract_t\">66</a>]. However, a relationship between type 2 diabetes and the promoter or coding regions of the glycogen synthase gene has not been confirmed [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/6,67\" class=\"abstract_t\">6,67</a>]. Furthermore, there is evidence that impaired insulin-stimulated glucose transport is responsible for the reduced muscle glycogen synthesis in patients with this disorder [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/68\" class=\"abstract_t\">68</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Hepatocyte nuclear factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Three of the recognized forms of what was formerly called maturity onset diabetes of the young (MODY1, MODY3, and MODY5) are due to mutations in the genes for hepatocyte nuclear factors 4-alpha, 1-alpha, and 1-beta, respectively, indicating that genes not directly related to insulin can be responsible for the development of diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/69,70\" class=\"abstract_t\">69,70</a>]. Genes in the <em>MODY1 </em>region of chromosome 20 and the <em>MODY3</em> region of chromosome 12 also contribute to the development of type 2 diabetes in whites [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/71,72\" class=\"abstract_t\">71,72</a>]. (See <a href=\"topic.htm?path=classification-of-diabetes-mellitus-and-genetic-diabetic-syndromes#H9\" class=\"medical medical_review\">&quot;Classification of diabetes mellitus and genetic diabetic syndromes&quot;, section on 'Maturity onset diabetes of the young'</a>.)</p><p class=\"headingAnchor\" id=\"H6585799\"><span class=\"h2\">Other genes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other genes that may affect susceptibility to type 2 diabetes are the genes for insulin-receptor substrates, the beta-3-adrenergic receptor, and peroxisome-proliferator-activated receptor (PPAR) gamma-2.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Insulin-receptor substrates are a common substrate for insulin receptor tyrosine kinases. Disruption of the <em>IRS-2</em> gene in mice results in insulin resistance in the liver and skeletal muscle and hyperglycemia because of an inadequate compensatory increase in insulin secretion [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/73\" class=\"abstract_t\">73</a>]. In another mouse study, upregulation of <em>IRS-2</em> in pancreatic beta cells could prevent the onset of diabetes caused by <em>IRS-2</em> disruption or diet-induced obesity [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/74\" class=\"abstract_t\">74</a>]. Other tissue-specific, <em>IRS-2</em> knockout (KO) mouse models suggest that <em>IRS-2</em> signaling may play an important role in hypothalamic regulation of leptin, peripheral insulin sensitivity, and, possibly, regeneration of beta cells [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/75,76\" class=\"abstract_t\">75,76</a>]. (See <a href=\"topic.htm?path=physiology-of-leptin\" class=\"medical medical_review\">&quot;Physiology of leptin&quot;</a> and <a href=\"topic.htm?path=structure-and-function-of-the-insulin-receptor\" class=\"medical medical_review\">&quot;Structure and function of the insulin receptor&quot;</a>.)</p><p/><p class=\"bulletIndent1\">In contrast, disruption of the <em>IRS-1</em> gene does not result in diabetes, because the insulin resistance is mild, and therefore, less of an increase in insulin secretion is needed to overcome it.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The beta-3-adrenergic receptor regulates lipolysis in visceral fat (the possible human component of brown fat in animals) and increases thermogenesis in this tissue. Initial observations in humans suggest that a mutation in the gene for the beta-3-adrenergic receptor is associated with a low metabolic rate, high risk of obesity, and the early onset of type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/77,78\" class=\"abstract_t\">77,78</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>PPAR gamma-2 is a transcription factor that has a key role in adipocyte differentiation. Polymorphisms in this gene may contribute to the variability in body mass index (BMI) and insulin sensitivity in the general population [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/79\" class=\"abstract_t\">79</a>]. The common Pro12Ala polymorphism of PPAR gamma has been associated with a modestly decreased risk for type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/80\" class=\"abstract_t\">80</a>]. PPAR gamma is also the receptor for the thiazolidinediones, which lower the blood glucose in type 2 diabetes by increasing insulin sensitivity. (See <a href=\"topic.htm?path=thiazolidinediones-in-the-treatment-of-diabetes-mellitus\" class=\"medical medical_review\">&quot;Thiazolidinediones in the treatment of diabetes mellitus&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It is possible that impaired action and secretion of insulin in type 2 diabetes share a common pathogenesis. In mice, a gain of function mutation in the Foxo1 gene (which encodes a transcription factor) targeted to the liver and pancreatic beta cells resulted in diabetes (due to an increase in hepatic glucose production and impaired beta cell compensation) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/81,82\" class=\"abstract_t\">81,82</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Calpain-10 locus on chromosome 2A (called <em>NIDDM1</em>) may confer major susceptibility to type 2 diabetes in Mexican Americans [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/83\" class=\"abstract_t\">83</a>]. It may also play a role in other populations [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/84,85\" class=\"abstract_t\">84,85</a>], but its contribution appears less than in Mexican Americans [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/84,86\" class=\"abstract_t\">84,86</a>]. The involved gene encodes calpain-10, a cysteine protease [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/84\" class=\"abstract_t\">84</a>].</p><p/><p class=\"bulletIndent1\">At least three polymorphisms within this gene can act in concert with a gene on chromosome 15 to increase the predisposition to the development of type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/84\" class=\"abstract_t\">84</a>]. How this occurs is not clear, but decreased insulin responsiveness plays at least a contributory role [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/86\" class=\"abstract_t\">86</a>]. Human immunodeficiency virus (HIV) protease inhibitors also are associated with the development of diabetes, suggesting that other proteases may be involved in diabetes susceptibility. (See <a href=\"topic.htm?path=classification-of-diabetes-mellitus-and-genetic-diabetic-syndromes\" class=\"medical medical_review\">&quot;Classification of diabetes mellitus and genetic diabetic syndromes&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>SLC16A11</em> was also identified as a candidate gene for type 2 diabetes in Mexican and Latin American individuals [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/47\" class=\"abstract_t\">47</a>]. Although common in Mexican populations (50 percent frequency in Native American samples), it is rare in European and African samples. Analysis of archaic genome sequence suggests that it is derived from Neanderthal introgression. It may play a role in lipid metabolism in the liver.</p><p/><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Animal models</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Additional insights into the genetic influences on the development of type 2 diabetes and on the requirement for both insulin resistance and a relative decrease in insulin secretion are provided by the phenotypes of double transgenic animals [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/87,88\" class=\"abstract_t\">87,88</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Double-KO mice homozygous for null alleles of genes for beta-cell glucokinase (which would impair insulin secretion) and <em>IRS-1</em> (which would impair insulin responsiveness) have overt diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/87\" class=\"abstract_t\">87</a>]. By comparison, single-KO mice lacking either one of these genes do not have diabetes.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another model, 40 percent of mice doubly heterozygous for null alleles of the insulin receptor and insulin receptor substrate-1 genes develop diabetes (with marked hyperinsulinemia and beta-cell hyperplasia) at the age of four to six months [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/88\" class=\"abstract_t\">88</a>]. In contrast, mice heterozygous for only one of these null alleles do not develop diabetes.</p><p/><p>These findings and the animal and human studies cited previously indicate that insulin resistance alone is insufficient to cause diabetes in humans [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/61,63,64\" class=\"abstract_t\">61,63,64</a>]. This requirement for multiple abnormalities in the expression and interaction of genes controlling insulin secretion and action may explain the non-Mendelian inheritance and the variable penetrance of type 2 diabetes.</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">ROLE OF DIET, OBESITY, AND INFLAMMATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The prevalence of impaired glucose tolerance and type 2 diabetes has increased dramatically in the United States population in the past two decades [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/2\" class=\"abstract_t\">2</a>]. The most striking features in these groups and of most patients who develop type 2 diabetes are increased weight gain and decreased physical activity, each of which increases the risk of diabetes (<a href=\"image.htm?imageKey=ENDO%2F79316\" class=\"graphic graphic_figure graphicRef79316 \">figure 5</a>) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=overweight-and-obesity-in-adults-health-consequences#H9\" class=\"medical medical_review\">&quot;Overweight and obesity in adults: Health consequences&quot;, section on 'Diabetes mellitus'</a>.)</p><p>Obesity, for example, causes peripheral resistance to insulin-mediated glucose uptake [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/9,89,90\" class=\"abstract_t\">9,89,90</a>] and may also decrease the sensitivity of the beta cells to glucose [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/90\" class=\"abstract_t\">90</a>]. These defects are largely reversed by weight loss, leading to a fall in blood glucose concentrations toward normal (see <a href=\"topic.htm?path=nutritional-considerations-in-type-2-diabetes-mellitus\" class=\"medical medical_review\">&quot;Nutritional considerations in type 2 diabetes mellitus&quot;</a>). Although not as effective as weight loss, an exercise regimen also may improve glucose tolerance and prevent the development of overt diabetes. (See <a href=\"topic.htm?path=prevention-of-type-2-diabetes-mellitus#H2741514022\" class=\"medical medical_review\">&quot;Prevention of type 2 diabetes mellitus&quot;, section on 'Exercise'</a>.)</p><p>The mechanism by which obesity induces insulin resistance is poorly understood. The pattern of fat distribution and perhaps a genetic abnormality in the beta-3-adrenergic receptor, as described above, appear to contribute. The c-Jun amino-terminal kinase (JNK) pathway may be an important mediator of the relationship between obesity and insulin resistance as JNK activity is increased in obesity, an effect that can interfere with insulin action. In animal models of obesity, absence of JNK1 results in decreased adiposity and enhanced insulin sensitivity [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/91\" class=\"abstract_t\">91</a>].</p><p>Many studies have focused on the role of inflammation as a common mediator linking obesity to both the pathogenesis of diabetes and atherosclerosis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/92,93\" class=\"abstract_t\">92,93</a>]. The incidence of type 2 diabetes has been correlated with increased levels of markers of inflammation, including C-reactive protein, interleukin (IL)-6, plasminogen activator inhibitor-1 (PAI-1), tumor necrosis factor-alpha (TNFa), and white cell count [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/94-97\" class=\"abstract_t\">94-97</a>]. Adipokines (factors released from adipose tissue) stimulate inflammatory activity, which correlates with insulin resistance, as demonstrated in mouse models. Intensive lifestyle interventions have been shown to decrease markers of inflammation [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/98\" class=\"abstract_t\">98</a>]. Anti-inflammatory properties of medications including thiazolidinediones and statins [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/99\" class=\"abstract_t\">99</a>] may contribute therapeutic benefit beyond their activity to lower glucose and cholesterol levels, respectively. Among patients with rheumatoid arthritis or psoriasis, use of anti-inflammatory, disease-modifying antirheumatic drugs, such as TNF inhibitors and <a href=\"topic.htm?path=hydroxychloroquine-drug-information\" class=\"drug drug_general\">hydroxychloroquine</a>, is associated with a lower incidence of diabetes than other agents [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/100\" class=\"abstract_t\">100</a>].</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Free fatty acids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Plasma free fatty acid (FFA) concentrations are high in obese patients. A high plasma FFA concentration is a risk factor for type 2 diabetes (relative risk 2.3) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/101\" class=\"abstract_t\">101</a>], may inhibit insulin secretion, and can inhibit insulin-stimulated glucose uptake in patients with type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/102\" class=\"abstract_t\">102</a>].</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Pattern of fat distribution</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Upper body or male-type obesity has a much greater association with insulin resistance and impaired glucose tolerance than lower body or female-type obesity (<a href=\"image.htm?imageKey=ENDO%2F56394\" class=\"graphic graphic_figure graphicRef56394 \">figure 6</a>). (See <a href=\"topic.htm?path=risk-factors-for-type-2-diabetes-mellitus#H6\" class=\"medical medical_review\">&quot;Risk factors for type 2 diabetes mellitus&quot;, section on 'Fat distribution'</a> and <a href=\"topic.htm?path=overweight-and-obesity-in-adults-health-consequences#H9\" class=\"medical medical_review\">&quot;Overweight and obesity in adults: Health consequences&quot;, section on 'Diabetes mellitus'</a>.)</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Factors released from adipose tissue</span></p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h3\">Leptin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Leptin is produced by adipocytes and is secreted in proportion to adipocyte mass. It signals the hypothalamus about the quantity of stored fat. Studies in humans and animals have shown that leptin deficiency and leptin resistance are associated with obesity and insulin resistance. (See <a href=\"topic.htm?path=physiology-of-leptin\" class=\"medical medical_review\">&quot;Physiology of leptin&quot;</a>.)</p><p>In addition to its hypothalamic actions, leptin also has biologic actions in peripheral tissues, such as the pancreas [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/103,104\" class=\"abstract_t\">103,104</a>]. In a preliminary study of a pancreas-specific, leptin receptor-knockout (KO) mouse model, the absence of leptin signaling was associated with improved glucose tolerance in KO mice compared with control mice when the mice were fed a standard diet [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/104\" class=\"abstract_t\">104</a>]. The administration of a high-fat diet resulted in weight gain and insulin resistance in both KO and control mice. The control mice developed islet-cell hyperplasia to compensate for insulin resistance. However, deterioration in the acute insulin response to glucose and poor islet-cell growth were seen in the KO mice. These results suggest conflicting roles for leptin, depending upon diet and presence of insulin resistance. Additional studies are required to determine if leptin is important for the regulation of beta-cell <span class=\"nowrap\">mass/function,</span> and whether abnormal leptin receptor signaling in islet cells plays a role in the pathogenesis of obesity-related type 2 diabetes.</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h3\">Adiponectin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Adiponectin, an adipocyte-derived cytokine, reduces levels of blood FFAs and has been associated with improved lipid profiles, better glycemic control, and reduced inflammation in diabetic patients [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/105\" class=\"abstract_t\">105</a>]. Adiponectin has also been inversely associated with risk for diabetes in the nondiabetic population [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/106\" class=\"abstract_t\">106</a>].</p><p>A number of observations suggest that deficiency of adiponectin, an adipocyte-derived hormone, plays a role in the development of insulin resistance and subsequent type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/107\" class=\"abstract_t\">107</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lower adiponectin levels are more closely related to the degree of insulin resistance and hyperinsulinemia than to the degree of adiposity and glucose intolerance [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/108\" class=\"abstract_t\">108</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a study of subjects with insulin resistance, administration of thiazolidinediones, which has been shown to decrease the development of diabetes, increased serum adiponectin concentrations without affecting body weight [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/109\" class=\"abstract_t\">109</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adiponectin is down-regulated in obesity [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/110\" class=\"abstract_t\">110</a>]. In obese or lipoatrophic mice, adiponectin administration decreases the degree of insulin resistance associated with these conditions [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/111\" class=\"abstract_t\">111</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In adiponectin-KO mice, plasma and adipocyte concentrations of TNFa increased, resulting in severe diet-induced insulin resistance [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/112\" class=\"abstract_t\">112</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Two adiponectin receptors have been cloned: AdipoR1 and AdipoR2, which are expressed primarily in skeletal muscle and the liver, respectively [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/113\" class=\"abstract_t\">113</a>].</p><p/><p>Adiponectin, and adiponectin receptors, may become an important target in the management of diabetes. Two studies have suggested that dietary cereal fiber and reduced glycemic load can increase adiponectin in diabetic men [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/114\" class=\"abstract_t\">114</a>] and women [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/115\" class=\"abstract_t\">115</a>].</p><p>In addition to its strong association with type 2 diabetes risk, preliminary data suggest that adiponectin may be moderately associated with cardiovascular morbidity and mortality. High adiponectin concentrations are associated with a favorable cardiovascular risk profile [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/116-118\" class=\"abstract_t\">116-118</a>]. However, the relationship is more complex. High adiponectin concentrations have also been associated with increased all-cause and cardiovascular mortality [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/119,120\" class=\"abstract_t\">119,120</a>]. The discrepancy may be related to the patient population studied (men versus women, older versus younger, prevalent cardiovascular disease). In addition, adiponectin may not directly affect cardiovascular risk, but may be a marker of other risks. Additional studies are needed to clarify the relationship between adiponectin and cardiovascular disease.</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h3\">Tumor necrosis factor-alpha</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Studies in genetically obese animals suggest that increased release of TNFa from adipose tissue may play a major role in the impairment in insulin action [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/121-124\" class=\"abstract_t\">121-124</a>]. This suggestion is based on the following observations: administration of anti-TNFa antibody led to marked improvement in glucose utilization in obese rats [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/121\" class=\"abstract_t\">121</a>], and obese mice genetically lacking TNFa have more normal insulin sensitivity [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/122\" class=\"abstract_t\">122</a>]. In another study, weight reduction in obese animals was associated with both improved insulin activity and decreased TNFa gene expression [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/123\" class=\"abstract_t\">123</a>].</p><p>A fatty acid-binding protein in adipocytes, aP2, may provide the link by which FFA in obesity leads to increased expression of TNFa in obesity. Targeted mutations in the gene for this protein are associated with obesity but not insulin resistance or increased TNFa expression [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/124\" class=\"abstract_t\">124</a>]. In addition, activation of Toll-like receptor 4 (TLR4) by nutritional fatty acids has been reported to increase TNFa and IL-6 [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/125\" class=\"abstract_t\">125</a>]. Thus, there may be more than one mechanism by which obesity induces insulin resistance.</p><p>The applicability of these findings to humans is uncertain. A preliminary study found a strong correlation among the degree of obesity, hyperinsulinemia, and TNFa mRNA in adipose tissue. In addition, in a study of a homogeneous Native Canadian population, plasma TNFa concentrations were positively correlated with insulin resistance [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/126\" class=\"abstract_t\">126</a>].</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h3\">Chemokine molecules</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chemokines (chemotactic proinflammatory cytokines) are a family of low molecular weight proteins that are potent chemoattractants of leukocytes and may modulate the formation of reactive oxygen species and cytokines. Chemokines specific for neutrophils, called CXC chemokines, are distinguished from other chemokines by a protein motif in which the first two cysteines are separated by one amino acid. CXC chemokines are produced by many different cell types, including endothelial cells, platelets, neutrophils, T lymphocytes, and monocytes.</p><p>The chemokine molecule CXCL5 (CXC ligand 5) is expressed at high levels in the macrophage fraction of white adipose tissue [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/127\" class=\"abstract_t\">127</a>]. When it binds to the chemokine receptor CXCR2, it reduces insulin-stimulated glucose uptake in muscle, suggesting a potential role of CXCL5 in mediating insulin resistance. In support of this hypothesis are the observations that serum levels of CXCL5 are higher in obese compared with normal-weight individuals and in insulin-resistant obese compared with noninsulin-resistant obese individuals [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/127\" class=\"abstract_t\">127</a>]. CXCL5 concentrations decrease with weight loss.</p><p>In addition, inhibition of CXCL5 via administration of a neutralizing antibody or a selective CXCR2 antagonist in two mice models of insulin resistance resulted in an improvement in insulin sensitivity [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/127\" class=\"abstract_t\">127</a>]. Thus, CXCL5 may be another link among obesity, inflammation, and insulin resistance.</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h3\">Plasminogen activator inhibitor</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PAI-1, an inhibitor of fibrinolysis, is another protein related to adipocytes. It is also secreted from endothelial cells, mononuclear cells, hepatocytes, and fibroblasts and has been associated with an increased risk for cardiovascular disease. A five-year prospective study of 2356 adults aged 70 to 79 years identified 143 new cases of diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/128\" class=\"abstract_t\">128</a>]. Elevated levels of PAI-1 were an independent predictor of onset of diabetes (odds ratio [OR] 1.35, 95% CI 1.01-1.81) after controlling for components of the metabolic syndrome (body mass index [BMI], visceral fat, lipids, hypertension, and fasting plasma glucose [FPG]); other adipocytokines, including adiponectin, TNFa, and leptin, did not independently predict diabetes.</p><p class=\"headingAnchor\" id=\"H26\"><span class=\"h3\">Resistin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In diet-induced or genetic obesity in mice, adipocytes secrete a signaling molecule named resistin. Administration of resistin decreases while neutralization of resistin increases insulin-mediated glucose uptake by adipocytes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/129\" class=\"abstract_t\">129</a>]. Hypothalamic administration of resistin also enhances glucose production, independent of changes in glucoregulatory hormones [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/130\" class=\"abstract_t\">130</a>]. Thus, resistin may be a hormone that links obesity to diabetes.</p><p class=\"headingAnchor\" id=\"H27\"><span class=\"h3\">Retinol-binding protein 4</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Retinol-binding protein 4 (RBP4), another protein released from adipocytes, correlates with the degree of insulin resistance in patients with obesity, impaired glucose tolerance, or type 2 diabetes, as well as in nonobese subjects with [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/131\" class=\"abstract_t\">131</a>] or without [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/132\" class=\"abstract_t\">132</a>] a strong family history of type 2 diabetes. Exercise training reduced RBP4 levels in patients whose insulin resistance improved with exercise. In a mouse model, mice lacking adipocyte glucose transporter 4 (GLUT4) had increased levels of RBP4, and RBP4 was shown to cause insulin resistance in mouse muscle and liver [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/133\" class=\"abstract_t\">133</a>]. An inverse relationship between GLUT4 in adipocytes and serum RBP4 was demonstrated in the human study, as well [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/131\" class=\"abstract_t\">131</a>]. Whether RBP4 in humans causes, or is correlated with, insulin resistance has not been determined.</p><p class=\"headingAnchor\" id=\"H28\"><span class=\"h2\">Other factors</span></p><p class=\"headingAnchor\" id=\"H29\"><span class=\"h3\">Interleukin-1 beta</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Another cytokine, interleukin-1 beta, a recognized inhibitor of glucose-induced insulin secretion, has been reported to undergo increased synthesis by the islet (presumably the beta cell itself) under conditions of high glucose concentrations [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/134\" class=\"abstract_t\">134</a>]. This raises the possibility of a negative downward spiral: chronic exposure to hyperglycemia leading to high concentrations of interleukin-1 beta within the islet, which in turn worsens beta-cell function. Interleukin-1 receptor antagonists, which decrease the activity of interleukin-1 beta, may therefore improve beta-cell function and glycemic control. (See <a href=\"topic.htm?path=management-of-persistent-hyperglycemia-in-type-2-diabetes-mellitus\" class=\"medical medical_review\">&quot;Management of persistent hyperglycemia in type 2 diabetes mellitus&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H30\"><span class=\"h3\">Uncoupling protein 2</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Uncoupling protein 2 (UCP2) is an inhibitor of insulin secretion [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/135\" class=\"abstract_t\">135</a>]. <span class=\"nowrap\">Ob/ob</span> mice are extremely obese, insulin-resistant, and diabetic, with increased levels of UCP2 in pancreatic islet cells. When UCP2-KO mice were crossed with <span class=\"nowrap\">ob/ob</span> mice to produce <span class=\"nowrap\">ob/ob</span> mice, the obesity and insulin resistance did not change, but the degree of hyperglycemia decreased as a result of increased insulin secretion [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/136\" class=\"abstract_t\">136</a>].</p><p>Animal studies suggest a possible additional genetic association between obesity and diabetes. Leptin, a hormone released from adipocytes, modulates body weight by regulating food intake and energy expenditure. (See <a href=\"topic.htm?path=genetic-contribution-and-pathophysiology-of-obesity\" class=\"medical medical_review\">&quot;Genetic contribution and pathophysiology of obesity&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H31\"><span class=\"h3\">Obestatin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Obestatin, a hormone that was isolated from rat stomach, is encoded by the ghrelin gene and opposes the effects of ghrelin on food intake (see <a href=\"topic.htm?path=ghrelin\" class=\"medical medical_review\">&quot;Ghrelin&quot;</a>). Treatment of rats with obestatin suppresses food intake, inhibits jejunal contraction, and decreases weight gain [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/137\" class=\"abstract_t\">137</a>]. Circulating obestatin concentrations are decreased in individuals with diabetes and impaired glucose tolerance compared with normal glucose tolerance [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/138\" class=\"abstract_t\">138</a>]. In addition, expression of the obestatin receptor in adipose tissue is downregulated in obesity-associated type 2 diabetes, but not in normoglycemic obese subjects, suggesting that obestatin may play a role in glucose regulation and development of type 2 diabetes independent of obesity [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/139\" class=\"abstract_t\">139</a>].</p><p class=\"headingAnchor\" id=\"H32\"><span class=\"h1\">ROLE OF INTRAUTERINE DEVELOPMENT</span></p><p class=\"headingAnchor\" id=\"H33\"><span class=\"h2\">Low birth weight</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The presence of insulin resistance in obesity and type 2 diabetes led to the theory of the &quot;thrifty&quot; genotype in which insulin resistance might improve survival during states of caloric deprivation but would lead to diabetes in states of caloric excess or even adequacy. However, other observations have suggested a different hypothesis: the thrifty genotype might be induced by malnutrition during fetal and early life. In particular, intrauterine growth restriction leading to low birth weight may be associated with an increased risk in adulthood of insulin resistance, glucose intolerance, type 2 diabetes, dyslipidemia, and hypertension [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/140-147\" class=\"abstract_t\">140-147</a>]. (See <a href=\"topic.htm?path=possible-role-of-low-birth-weight-in-the-pathogenesis-of-primary-essential-hypertension\" class=\"medical medical_review\">&quot;Possible role of low birth weight in the pathogenesis of primary (essential) hypertension&quot;</a>.)</p><p>The inverse relationship between birth weight and diabetes mellitus was illustrated in an analysis from the Nurses' Health Study of over 69,000 women [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/148\" class=\"abstract_t\">148</a>]. The relative risk of type 2 diabetes compared with a reference group by ascending birth weight categories decreased progressively from 1.8 for a birth weight less than 2.3 kg to 0.8 for a birth weight greater than 4.5 kg. Adjustment for ethnicity, childhood socioeconomic status, and adult lifestyle factors did not substantially alter this association. A meta-analysis of 30 studies, including the Nurses' Health Study, confirmed the inverse association between birth weight and type 2 diabetes (adjusted odds ratio [OR] of diabetes 0.80, 95% CI 0.72-0.89 for each 1-kg increase in birth weight) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/149\" class=\"abstract_t\">149</a>].</p><p>Thus, thinness at birth and in adult life have opposing effects on insulin resistance, such that subjects who were <strong>underweight at birth</strong> but who become overweight in middle age have the most severe insulin resistance and the greatest risk for type 2 diabetes (<a href=\"image.htm?imageKey=ENDO%2F52859\" class=\"graphic graphic_figure graphicRef52859 \">figure 7</a>) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/140\" class=\"abstract_t\">140</a>]. Even among infants with a normal birth weight (&ge;3.5 kg), those who had slow growth in length in the first three months after birth were more likely to develop diabetes later in life, suggesting that the critical period for pancreatic beta-cell development extends beyond the intrauterine period [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/145\" class=\"abstract_t\">145</a>].</p><p class=\"headingAnchor\" id=\"H34\"><span class=\"h2\">High birth weight</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Higher birth weight (&gt;4.0 kg) may also be associated with an increased risk of diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/150\" class=\"abstract_t\">150</a>]. A meta-analysis of 14 studies (involving 132,180 individuals) of birth weight and subsequent risk of type 2 diabetes demonstrated a U-shaped relationship between birth weight and diabetes risk [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/151\" class=\"abstract_t\">151</a>]. High birth weight was associated with increased risk of diabetes in later life to the same extent as low birth weight (ORs 1.36 versus 1.47).</p><p>The association between high birth weight and risk of type 2 diabetes may be related to maternal hyperglycemia during pregnancy. Prenatal exposure to hyperglycemia may increase the risk of type 2 diabetes, independent of genetic predisposition. This was demonstrated in a study of 31 nondiabetic adults, 15 of whom were exposed to a diabetic environment in utero (mothers with type 1 diabetes) and 15 who had not been exposed but whose fathers had type 1 diabetes (controls). The exposed subjects had an increased risk of impaired glucose tolerance (5 of 15 versus 0 of 16), and a defective insulin secretory response when compared with control subjects [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/152\" class=\"abstract_t\">152</a>]. (See <a href=\"topic.htm?path=infant-of-a-diabetic-mother\" class=\"medical medical_review\">&quot;Infant of a diabetic mother&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H35\"><span class=\"h2\">Prematurity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children born prematurely, whether they were appropriate or small for gestational age, may also be at increased risk for type 2 diabetes and other diseases of adulthood associated with insulin resistance. This was illustrated in a study of 50 healthy children ages 4 to 10 years who had been born prematurely (&lt;32 weeks gestation; 38 with a birth weight that was appropriate for gestational age and 12 who were small for gestational age) and 22 control subjects (&ge;37 weeks gestation with a normal birth weight) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/153\" class=\"abstract_t\">153</a>]. A similar reduction in insulin sensitivity (as measured by paired insulin and glucose values on an intravenous glucose tolerance tests) was seen in both groups of children born prematurely (normal or small for gestational age) when compared with the control group. The alteration in insulin dynamics appears to be present at birth. However, measurements in <span class=\"nowrap\">neonates/infants</span> are limited. In a prospective birth cohort of 1358 children (418 born preterm), there was an inverse association between gestational age (regardless of birth weight for gestational age) and elevated plasma insulin levels at birth [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/154\" class=\"abstract_t\">154</a>]. Plasma insulin levels in early childhood were also inversely associated with gestational age, but the association was attenuated after adjustment for rapid weight gain in the first year of life. In another study, the reduction in insulin sensitivity associated with preterm birth persisted into adulthood [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/155\" class=\"abstract_t\">155</a>]. The implications for future development of type 2 diabetes require further study.</p><p class=\"headingAnchor\" id=\"H36\"><span class=\"h1\">DRUG-INDUCED HYPERGLYCEMIA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A large number of drugs can impair glucose tolerance; they act by decreasing insulin secretion, increasing hepatic glucose production, or causing resistance to the action of insulin (<a href=\"image.htm?imageKey=ENDO%2F67257\" class=\"graphic graphic_table graphicRef67257 \">table 2</a>). Included in this list are glucocorticoids, oral contraceptives, several classes of antihypertensive drugs such as beta blockers, thiazide diuretics, nicotinic acid, statins, protease inhibitors used for the treatment of human immunodeficiency virus (HIV) infection, gonadotropin-releasing hormone (GnRH) agonists used for the treatment of prostate cancer, <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a>, <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a>, and <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> used primarily to prevent transplant rejection, and some of the atypical antipsychotic agents [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/156\" class=\"abstract_t\">156</a>]. (See <a href=\"topic.htm?path=major-side-effects-of-systemic-glucocorticoids\" class=\"medical medical_review\">&quot;Major side effects of systemic glucocorticoids&quot;</a> and <a href=\"topic.htm?path=risks-and-side-effects-associated-with-estrogen-progestin-contraceptives\" class=\"medical medical_review\">&quot;Risks and side effects associated with estrogen-progestin contraceptives&quot;</a> and <a href=\"topic.htm?path=low-density-lipoprotein-cholesterol-lowering-with-drugs-other-than-statins-and-pcsk9-inhibitors\" class=\"medical medical_review\">&quot;Low density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors&quot;</a> and <a href=\"topic.htm?path=statins-actions-side-effects-and-administration#H17\" class=\"medical medical_review\">&quot;Statins: Actions, side effects, and administration&quot;, section on 'Diabetes mellitus'</a> and <a href=\"topic.htm?path=lipodystrophic-syndromes#H25\" class=\"medical medical_review\">&quot;Lipodystrophic syndromes&quot;, section on 'Lipodystrophy associated with HIV therapy'</a> and <a href=\"topic.htm?path=side-effects-of-androgen-deprivation-therapy\" class=\"medical medical_review\">&quot;Side effects of androgen deprivation therapy&quot;</a> and <a href=\"topic.htm?path=pharmacology-of-cyclosporine-and-tacrolimus#H21\" class=\"medical medical_review\">&quot;Pharmacology of cyclosporine and tacrolimus&quot;, section on 'Metabolic abnormalities'</a> and <a href=\"topic.htm?path=major-side-effects-of-inhaled-glucocorticoids#H17\" class=\"medical medical_review\">&quot;Major side effects of inhaled glucocorticoids&quot;, section on 'Other potential concerns'</a>.)</p><p class=\"headingAnchor\" id=\"H37\"><span class=\"h2\">Thiazide diuretics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment with thiazide diuretics is associated with an increase in fasting plasma glucose (FPG) and risk of developing type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/157,158\" class=\"abstract_t\">157,158</a>]. However, a substantial increase in FPG is unusual, even in patients with type 2 diabetes, with the currently recommended regimen of low-dose thiazide therapy (eg, 12.5 to a maximum of 25 mg of <a href=\"topic.htm?path=hydrochlorothiazide-drug-information\" class=\"drug drug_general\">hydrochlorothiazide</a>) (<a href=\"image.htm?imageKey=NEPH%2F69912\" class=\"graphic graphic_figure graphicRef69912 \">figure 8</a>) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/159-161\" class=\"abstract_t\">159-161</a>]. Concurrent hypokalemia appears to play an important role, as evidenced by a small study showing no change in glucose tolerance if urinary losses are replaced by potassium supplements [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/162\" class=\"abstract_t\">162</a>]. Subsequent analyses of larger trials confirmed the association between hypokalemia and a higher probability of developing type 2 diabetes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/163,164\" class=\"abstract_t\">163,164</a>]. As an example, in the Systolic Hypertension in Elderly Program trial, the risk of diabetes with use of a thiazide (<a href=\"topic.htm?path=chlorthalidone-drug-information\" class=\"drug drug_general\">chlorthalidone</a>) was significantly attenuated when adjusted for changes in serum potassium [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/163\" class=\"abstract_t\">163</a>]. Each 0.5 <span class=\"nowrap\">mEq/L</span> decrease in serum potassium was associated with a 45 percent higher risk of new diabetes. The putative mechanism for this association is a failure of potassium channels to close in response to rising plasma glucose concentrations, with a resultant decrease in insulin secretion. (See <a href=\"topic.htm?path=treatment-of-hypertension-in-patients-with-diabetes-mellitus\" class=\"medical medical_review\">&quot;Treatment of hypertension in patients with diabetes mellitus&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H38\"><span class=\"h2\">Antipsychotics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with preexisting diabetes, the initiation of atypical or typical antipsychotic agents has been associated with worsening hyperglycemia [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/165\" class=\"abstract_t\">165</a>]. In addition, some of the atypical antipsychotic agents, in particular, <a href=\"topic.htm?path=clozapine-drug-information\" class=\"drug drug_general\">clozapine</a> and <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a>, have been associated with weight gain, obesity, hypertriglyceridemia, and development of diabetes mellitus [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/166-168\" class=\"abstract_t\">166-168</a>]. The mechanism(s) by which they cause the metabolic syndrome have not been defined. An American Diabetes Association (ADA) consensus panel concluded that data on <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">risperidone</a> and <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> show an increased risk for weight gain but conflicting data on diabetes and dyslipidemia risk [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/169\" class=\"abstract_t\">169</a>]. The panel also concluded that patients taking <a href=\"topic.htm?path=ziprasidone-drug-information\" class=\"drug drug_general\">ziprasidone</a> and <a href=\"topic.htm?path=aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-drug-information\" class=\"drug drug_general\">aripiprazole</a> are not at increased risk for developing diabetes or dyslipidemia.</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=type-2-diabetes-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Type 2 diabetes (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=diabetes-mellitus-type-2-overview-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Diabetes mellitus type 2: Overview (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H40\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Type 2 diabetes mellitus is caused by a combination of varying degrees of insulin resistance and relative insulin deficiency. Its occurrence most likely represents a complex interaction among many genes and environmental factors, which are different among different populations and individuals. (See <a href=\"#H2\" class=\"local\">'Pathophysiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The search for plausible candidate genes has focused upon genes coding for proteins that might be involved in pancreatic development, insulin synthesis, secretion, or action. (See <a href=\"#H8\" class=\"local\">'Genetic susceptibility'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The most striking environmental risk factors in most patients who develop type 2 diabetes are increased weight gain and decreased physical activity, each of which increases the risk of diabetes. (See <a href=\"#H17\" class=\"local\">'Role of diet, obesity, and inflammation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The mechanism by which obesity induces insulin resistance is poorly understood. Inflammation may be the common mediator linking obesity to the pathogenesis of diabetes. (See <a href=\"#H17\" class=\"local\">'Role of diet, obesity, and inflammation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A large number of drugs can impair glucose tolerance. They act by decreasing insulin secretion, increasing hepatic glucose production, or causing resistance to the action of insulin (<a href=\"image.htm?imageKey=ENDO%2F67257\" class=\"graphic graphic_table graphicRef67257 \">table 2</a>). (See <a href=\"#H36\" class=\"local\">'Drug-induced hyperglycemia'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/1\" class=\"nounderline abstract_t\">Harris MI. Impaired glucose tolerance in the U.S. population. Diabetes Care 1989; 12:464.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/2\" class=\"nounderline abstract_t\">Engelgau MM, Geiss LS, Saaddine JB, et al. The evolving diabetes burden in the United States. Ann Intern Med 2004; 140:945.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/3\" class=\"nounderline abstract_t\">Sullivan PW, Morrato EH, Ghushchyan V, et al. Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002. Diabetes Care 2005; 28:1599.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/4\" class=\"nounderline abstract_t\">Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365:1333.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/5\" class=\"nounderline abstract_t\">Beck-Nielsen H, Groop LC. Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest 1994; 94:1714.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/6\" class=\"nounderline abstract_t\">Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994; 43:1066.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/7\" class=\"nounderline abstract_t\">Robertson RP. Antagonist: diabetes and insulin resistance--philosophy, science, and the multiplier hypothesis. J Lab Clin Med 1995; 125:560.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/8\" class=\"nounderline abstract_t\">Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004; 27:2597.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/9\" class=\"nounderline abstract_t\">DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14:173.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/10\" class=\"nounderline abstract_t\">Chen KW, Boyko EJ, Bergstrom RW, et al. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men. Diabetes Care 1995; 18:747.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/11\" class=\"nounderline abstract_t\">Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes 1995; 44:1386.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/12\" class=\"nounderline abstract_t\">Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104:787.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/13\" class=\"nounderline abstract_t\">Tab&aacute;k AG, Jokela M, Akbaraly TN, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009; 373:2215.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/14\" class=\"nounderline abstract_t\">Ohtsubo K, Takamatsu S, Minowa MT, et al. Dietary and genetic control of glucose transporter 2 glycosylation promotes insulin secretion in suppressing diabetes. Cell 2005; 123:1307.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/15\" class=\"nounderline abstract_t\">Thorens B. A toggle for type 2 diabetes? N Engl J Med 2006; 354:1636.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/16\" class=\"nounderline abstract_t\">Brunham LR, Kruit JK, Pape TD, et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 2007; 13:340.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/17\" class=\"nounderline abstract_t\">Sigal RJ, El-Hashimy M, Martin BC, et al. Acute postchallenge hyperinsulinemia predicts weight gain: a prospective study. Diabetes 1997; 46:1025.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/18\" class=\"nounderline abstract_t\">Odeleye OE, de Courten M, Pettitt DJ, Ravussin E. Fasting hyperinsulinemia is a predictor of increased body weight gain and obesity in Pima Indian children. Diabetes 1997; 46:1341.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/19\" class=\"nounderline abstract_t\">Moran A, Zhang HJ, Olson LK, et al. Differentiation of glucose toxicity from beta cell exhaustion during the evolution of defective insulin gene expression in the pancreatic islet cell line, HIT-T15. J Clin Invest 1997; 99:534.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/20\" class=\"nounderline abstract_t\">Rothman DL, Magnusson I, Cline G, et al. Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 1995; 92:983.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/21\" class=\"nounderline abstract_t\">Petersen KF, Dufour S, Befroy D, et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350:664.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/22\" class=\"nounderline abstract_t\">Kahn SE, Halban PA. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 1997; 46:1725.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/23\" class=\"nounderline abstract_t\">R&oslash;der ME, Dinesen B, Hartling SG, et al. Intact proinsulin and beta-cell function in lean and obese subjects with and without type 2 diabetes. Diabetes Care 1999; 22:609.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/24\" class=\"nounderline abstract_t\">Westermark P, Johnson KH, O'Brien TD, Betsholtz C. Islet amyloid polypeptide--a novel controversy in diabetes research. Diabetologia 1992; 35:297.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/25\" class=\"nounderline abstract_t\">M&auml;kimattila S, Fineman MS, Yki-J&auml;rvinen H. Deficiency of total and nonglycosylated amylin in plasma characterizes subjects with impaired glucose tolerance and type 2 diabetes. J Clin Endocrinol Metab 2000; 85:2822.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/26\" class=\"nounderline abstract_t\">Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 2004; 89:3629.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/27\" class=\"nounderline abstract_t\">Wilding JP, Khandan-Nia N, Bennet WM, et al. Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans. Diabetologia 1994; 37:166.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/28\" class=\"nounderline abstract_t\">Bennet WM, Beis CS, Ghatei MA, et al. Amylin tonally regulates arginine-stimulated insulin secretion in rats. Diabetologia 1994; 37:436.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/29\" class=\"nounderline abstract_t\">Gurlo T, Ryazantsev S, Huang CJ, et al. Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am J Pathol 2010; 176:861.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/30\" class=\"nounderline abstract_t\">Bell GI, Froguel P, Nishi S, et al. Mutations of the human glucokinase gene and diabetes mellitus. Trends Endocrinol Metab 1993; 4:86.</a></li><li class=\"breakAll\">Bennett, PH. Epidemiology of diabetes mellitus. In: Ellenberg and Rifkin's Diabetes Mellitus, Rifkin, H, Porte, D Jr (Eds), Elsevier, New York 1990. p.363.</li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/32\" class=\"nounderline abstract_t\">Carter JS, Pugh JA, Monterrosa A. Non-insulin-dependent diabetes mellitus in minorities in the United States. Ann Intern Med 1996; 125:221.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/33\" class=\"nounderline abstract_t\">Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998; 21:518.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/34\" class=\"nounderline abstract_t\">Klein BE, Klein R, Moss SE, Cruickshanks KJ. Parental history of diabetes in a population-based study. Diabetes Care 1996; 19:827.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/35\" class=\"nounderline abstract_t\">Barnett AH, Eff C, Leslie RD, Pyke DA. Diabetes in identical twins. A study of 200 pairs. Diabetologia 1981; 20:87.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/36\" class=\"nounderline abstract_t\">Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989; 321:337.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/37\" class=\"nounderline abstract_t\">Knowles NG, Landchild MA, Fujimoto WY, Kahn SE. Insulin and amylin release are both diminished in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 2002; 25:292.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/38\" class=\"nounderline abstract_t\">Schulz LO, Bennett PH, Ravussin E, et al. Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the U.S. Diabetes Care 2006; 29:1866.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/39\" class=\"nounderline abstract_t\">Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007; 445:881.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/40\" class=\"nounderline abstract_t\">Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research, Saxena R, Voight BF, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316:1331.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/41\" class=\"nounderline abstract_t\">Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007; 316:1341.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/42\" class=\"nounderline abstract_t\">Zeggini E, Weedon MN, Lindgren CM, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007; 316:1336.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/43\" class=\"nounderline abstract_t\">Steinthorsdottir V, Thorleifsson G, Reynisdottir I, et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 2007; 39:770.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/44\" class=\"nounderline abstract_t\">Zeggini E, Scott LJ, Saxena R, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008; 40:638.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/45\" class=\"nounderline abstract_t\">Yasuda K, Miyake K, Horikawa Y, et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 2008; 40:1092.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/46\" class=\"nounderline abstract_t\">Unoki H, Takahashi A, Kawaguchi T, et al. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet 2008; 40:1098.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/47\" class=\"nounderline abstract_t\">SIGMA Type 2 Diabetes Consortium, Williams AL, Jacobs SB, et al. Sequence variants in SLC16A11 are a common risk factor for type 2 diabetes in Mexico. Nature 2014; 506:97.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/48\" class=\"nounderline abstract_t\">Voight BF, Scott LJ, Steinthorsdottir V, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010; 42:579.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/49\" class=\"nounderline abstract_t\">Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38:320.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/50\" class=\"nounderline abstract_t\">Florez JC, Jablonski KA, Bayley N, et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006; 355:241.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/51\" class=\"nounderline abstract_t\">Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007; 117:2155.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/52\" class=\"nounderline abstract_t\">Froguel P, Zouali H, Vionnet N, et al. Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N Engl J Med 1993; 328:697.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/53\" class=\"nounderline abstract_t\">Chiu KC, Province MA, Permutt MA. Glucokinase gene is genetic marker for NIDDM in American blacks. Diabetes 1992; 41:843.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/54\" class=\"nounderline abstract_t\">Cook JT, Hattersley AT, Christopher P, et al. Linkage analysis of glucokinase gene with NIDDM in Caucasian pedigrees. Diabetes 1992; 41:1496.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/55\" class=\"nounderline abstract_t\">Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet 1997; 17:138.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/56\" class=\"nounderline abstract_t\">Macfarlane WM, Frayling TM, Ellard S, et al. Missense mutations in the insulin promoter factor-1 gene predispose to type 2 diabetes. J Clin Invest 1999; 104:R33.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/57\" class=\"nounderline abstract_t\">Hart AW, Baeza N, Apelqvist A, Edlund H. Attenuation of FGF signalling in mouse beta-cells leads to diabetes. Nature 2000; 408:864.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/58\" class=\"nounderline abstract_t\">Hani EH, Stoffers DA, Ch&egrave;vre JC, et al. Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. J Clin Invest 1999; 104:R41.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/59\" class=\"nounderline abstract_t\">Rosengren AH, Jokubka R, Tojjar D, et al. Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes. Science 2010; 327:217.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/60\" class=\"nounderline abstract_t\">Gribble FM. Alpha2A-adrenergic receptors and type 2 diabetes. N Engl J Med 2010; 362:361.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/61\" class=\"nounderline abstract_t\">Moller DE, Flier JS. Insulin resistance--mechanisms, syndromes, and implications. N Engl J Med 1991; 325:938.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/62\" class=\"nounderline abstract_t\">Kido Y, Burks DJ, Withers D, et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest 2000; 105:199.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/63\" class=\"nounderline abstract_t\">McCulloch DK, Kahn SE, Schwartz MW, et al. Effect of nicotinic acid-induced insulin resistance on pancreatic B cell function in normal and streptozocin-treated baboons. J Clin Invest 1991; 87:1395.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/64\" class=\"nounderline abstract_t\">Lauro D, Kido Y, Castle AL, et al. Impaired glucose tolerance in mice with a targeted impairment of insulin action in muscle and adipose tissue. Nat Genet 1998; 20:294.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/65\" class=\"nounderline abstract_t\">Seldin MF, Mott D, Bhat D, et al. Glycogen synthase: a putative locus for diet-induced hyperglycemia. J Clin Invest 1994; 94:269.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/66\" class=\"nounderline abstract_t\">Groop LC, Kankuri M, Schalin-J&auml;ntti C, et al. Association between polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus. N Engl J Med 1993; 328:10.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/67\" class=\"nounderline abstract_t\">Bj&oslash;rbaek C, Echwald SM, Hubricht P, et al. Genetic variants in promoters and coding regions of the muscle glycogen synthase and the insulin-responsive GLUT4 genes in NIDDM. Diabetes 1994; 43:976.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/68\" class=\"nounderline abstract_t\">Cline GW, Petersen KF, Krssak M, et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 1999; 341:240.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/69\" class=\"nounderline abstract_t\">Yamagata K, Oda N, Kaisaki PJ, et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 1996; 384:455.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/70\" class=\"nounderline abstract_t\">Yamagata K, Furuta H, Oda N, et al. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature 1996; 384:458.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/71\" class=\"nounderline abstract_t\">Ji L, Malecki M, Warram JH, et al. New susceptibility locus for NIDDM is localized to human chromosome 20q. Diabetes 1997; 46:876.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/72\" class=\"nounderline abstract_t\">Mahtani MM, Wid&eacute;n E, Lehto M, et al. Mapping of a gene for type 2 diabetes associated with an insulin secretion defect by a genome scan in Finnish families. Nat Genet 1996; 14:90.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/73\" class=\"nounderline abstract_t\">Withers DJ, Gutierrez JS, Towery H, et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998; 391:900.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/74\" class=\"nounderline abstract_t\">Hennige AM, Burks DJ, Ozcan U, et al. Upregulation of insulin receptor substrate-2 in pancreatic beta cells prevents diabetes. J Clin Invest 2003; 112:1521.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/75\" class=\"nounderline abstract_t\">Kubota N, Terauchi Y, Tobe K, et al. Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J Clin Invest 2004; 114:917.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/76\" class=\"nounderline abstract_t\">Lin X, Taguchi A, Park S, et al. Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes. J Clin Invest 2004; 114:908.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/77\" class=\"nounderline abstract_t\">Walston J, Silver K, Bogardus C, et al. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. N Engl J Med 1995; 333:343.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/78\" class=\"nounderline abstract_t\">Wid&eacute;n E, Lehto M, Kanninen T, et al. Association of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 1995; 333:348.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/79\" class=\"nounderline abstract_t\">Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20:284.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/80\" class=\"nounderline abstract_t\">Gouda HN, Sagoo GS, Harding AH, et al. The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol 2010; 171:645.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/81\" class=\"nounderline abstract_t\">Nakae J, Biggs WH 3rd, Kitamura T, et al. Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet 2002; 32:245.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/82\" class=\"nounderline abstract_t\">Kitamura T. The role of FOXO1 in &beta;-cell failure and type 2 diabetes mellitus. Nat Rev Endocrinol 2013; 9:615.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/83\" class=\"nounderline abstract_t\">Hanis CL, Boerwinkle E, Chakraborty R, et al. A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat Genet 1996; 13:161.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/84\" class=\"nounderline abstract_t\">Horikawa Y, Oda N, Cox NJ, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000; 26:163.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/85\" class=\"nounderline abstract_t\">Hani EH, Hager J, Philippi A, et al. Mapping NIDDM susceptibility loci in French families: studies with markers in the region of NIDDM1 on chromosome 2q. Diabetes 1997; 46:1225.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/86\" class=\"nounderline abstract_t\">Baier LJ, Permana PA, Yang X, et al. A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. J Clin Invest 2000; 106:R69.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/87\" class=\"nounderline abstract_t\">Terauchi Y, Iwamoto K, Tamemoto H, et al. Development of non-insulin-dependent diabetes mellitus in the double knockout mice with disruption of insulin receptor substrate-1 and beta cell glucokinase genes. Genetic reconstitution of diabetes as a polygenic disease. J Clin Invest 1997; 99:861.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/88\" class=\"nounderline abstract_t\">Br&uuml;ning JC, Winnay J, Bonner-Weir S, et al. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 1997; 88:561.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/89\" class=\"nounderline abstract_t\">Friedman JE, Dohm GL, Leggett-Frazier N, et al. Restoration of insulin responsiveness in skeletal muscle of morbidly obese patients after weight loss. Effect on muscle glucose transport and glucose transporter GLUT4. J Clin Invest 1992; 89:701.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/90\" class=\"nounderline abstract_t\">Henry RR, Scheaffer L, Olefsky JM. Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1985; 61:917.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/91\" class=\"nounderline abstract_t\">Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420:333.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/92\" class=\"nounderline abstract_t\">Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116:1793.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/93\" class=\"nounderline abstract_t\">Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17:179.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/94\" class=\"nounderline abstract_t\">Duncan BB, Schmidt MI, Pankow JS, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003; 52:1799.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/95\" class=\"nounderline abstract_t\">Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286:327.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/96\" class=\"nounderline abstract_t\">Vozarova B, Weyer C, Lindsay RS, et al. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002; 51:455.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/97\" class=\"nounderline abstract_t\">de Rekeneire N, Peila R, Ding J, et al. Diabetes, hyperglycemia, and inflammation in older individuals: the health, aging and body composition study. Diabetes Care 2006; 29:1902.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/98\" class=\"nounderline abstract_t\">Haffner S, Temprosa M, Crandall J, et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005; 54:1566.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/99\" class=\"nounderline abstract_t\">Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 2006; 48:396.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/100\" class=\"nounderline abstract_t\">Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011; 305:2525.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/101\" class=\"nounderline abstract_t\">Paolisso G, Tataranni PA, Foley JE, et al. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 1995; 38:1213.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/102\" class=\"nounderline abstract_t\">Boden G, Chen X. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest 1995; 96:1261.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/103\" class=\"nounderline abstract_t\">Morioka T, Asilmaz E, Hu J, et al. Disruption of leptin receptor expression in the pancreas directly affects beta cell growth and function in mice. J Clin Invest 2007; 117:2860.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/104\" class=\"nounderline abstract_t\">Niswender KD, Magnuson MA. Obesity and the beta cell: lessons from leptin. J Clin Invest 2007; 117:2753.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/105\" class=\"nounderline abstract_t\">Mantzoros CS, Li T, Manson JE, et al. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 2005; 90:4542.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/106\" class=\"nounderline abstract_t\">Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009; 302:179.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/107\" class=\"nounderline abstract_t\">Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116:1784.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/108\" class=\"nounderline abstract_t\">Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86:1930.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/109\" class=\"nounderline abstract_t\">Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50:2094.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/110\" class=\"nounderline abstract_t\">Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257:79.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/111\" class=\"nounderline abstract_t\">Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7:941.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/112\" class=\"nounderline abstract_t\">Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8:731.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/113\" class=\"nounderline abstract_t\">Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423:762.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/114\" class=\"nounderline abstract_t\">Qi L, Rimm E, Liu S, et al. Dietary glycemic index, glycemic load, cereal fiber, and plasma adiponectin concentration in diabetic men. Diabetes Care 2005; 28:1022.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/115\" class=\"nounderline abstract_t\">Qi L, Meigs JB, Liu S, et al. Dietary fibers and glycemic load, obesity, and plasma adiponectin levels in women with type 2 diabetes. Diabetes Care 2006; 29:1501.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/116\" class=\"nounderline abstract_t\">Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291:1730.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/117\" class=\"nounderline abstract_t\">Han SH, Quon MJ, Kim JA, Koh KK. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007; 49:531.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/118\" class=\"nounderline abstract_t\">Sattar N, Wannamethee G, Sarwar N, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006; 114:623.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/119\" class=\"nounderline abstract_t\">Wannamethee SG, Whincup PH, Lennon L, Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 2007; 167:1510.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/120\" class=\"nounderline abstract_t\">Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol 2007; 165:164.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/121\" class=\"nounderline abstract_t\">Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259:87.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/122\" class=\"nounderline abstract_t\">Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389:610.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/123\" class=\"nounderline abstract_t\">Hofmann C, Lorenz K, Braithwaite SS, et al. Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 1994; 134:264.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/124\" class=\"nounderline abstract_t\">Hotamisligil GS, Johnson RS, Distel RJ, et al. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996; 274:1377.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/125\" class=\"nounderline abstract_t\">Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116:3015.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/126\" class=\"nounderline abstract_t\">Zinman B, Hanley AJ, Harris SB, et al. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 1999; 84:272.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/127\" class=\"nounderline abstract_t\">Chavey C, Lazennec G, Lagarrigue S, et al. CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance. Cell Metab 2009; 9:339.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/128\" class=\"nounderline abstract_t\">Kanaya AM, Wassel Fyr C, Vittinghoff E, et al. Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1. Arch Intern Med 2006; 166:350.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/129\" class=\"nounderline abstract_t\">Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409:307.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/130\" class=\"nounderline abstract_t\">Muse ED, Lam TK, Scherer PE, Rossetti L. Hypothalamic resistin induces hepatic insulin resistance. J Clin Invest 2007; 117:1670.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/131\" class=\"nounderline abstract_t\">Graham TE, Yang Q, Bl&uuml;her M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354:2552.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/132\" class=\"nounderline abstract_t\">Gavi S, Stuart LM, Kelly P, et al. Retinol-binding protein 4 is associated with insulin resistance and body fat distribution in nonobese subjects without type 2 diabetes. J Clin Endocrinol Metab 2007; 92:1886.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/133\" class=\"nounderline abstract_t\">Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436:356.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/134\" class=\"nounderline abstract_t\">Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110:851.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/135\" class=\"nounderline abstract_t\">Langin D. Diabetes, insulin secretion, and the pancreatic beta-cell mitochondrion. N Engl J Med 2001; 345:1772.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/136\" class=\"nounderline abstract_t\">Zhang CY, Baffy G, Perret P, et al. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell 2001; 105:745.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/137\" class=\"nounderline abstract_t\">Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005; 310:996.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/138\" class=\"nounderline abstract_t\">Qi X, Li L, Yang G, et al. Circulating obestatin levels in normal subjects and in patients with impaired glucose regulation and type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2007; 66:593.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/139\" class=\"nounderline abstract_t\">Catal&aacute;n V, G&oacute;mez-Ambrosi J, Rotellar F, et al. The obestatin receptor (GPR39) is expressed in human adipose tissue and is down-regulated in obesity-associated type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2007; 66:598.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/140\" class=\"nounderline abstract_t\">Phillips DI, Barker DJ, Hales CN, et al. Thinness at birth and insulin resistance in adult life. Diabetologia 1994; 37:150.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/141\" class=\"nounderline abstract_t\">Phillips DI, Hirst S, Clark PM, et al. Fetal growth and insulin secretion in adult life. Diabetologia 1994; 37:592.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/142\" class=\"nounderline abstract_t\">Valdez R, Athens MA, Thompson GH, et al. Birthweight and adult health outcomes in a biethnic population in the USA. Diabetologia 1994; 37:624.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/143\" class=\"nounderline abstract_t\">Fors&eacute;n T, Eriksson J, Tuomilehto J, et al. The fetal and childhood growth of persons who develop type 2 diabetes. Ann Intern Med 2000; 133:176.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/144\" class=\"nounderline abstract_t\">Bhargava SK, Sachdev HS, Fall CH, et al. Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med 2004; 350:865.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/145\" class=\"nounderline abstract_t\">Eriksson JG, Forsen TJ, Osmond C, Barker DJ. Pathways of infant and childhood growth that lead to type 2 diabetes. Diabetes Care 2003; 26:3006.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/146\" class=\"nounderline abstract_t\">Burke JP, Forsgren J, Palumbo PJ, et al. Association of birth weight and type 2 diabetes in Rochester, Minnesota. Diabetes Care 2004; 27:2512.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/147\" class=\"nounderline abstract_t\">Lawlor DA, Davey Smith G, Clark H, Leon DA. The associations of birthweight, gestational age and childhood BMI with type 2 diabetes: findings from the Aberdeen Children of the 1950s cohort. Diabetologia 2006; 49:2614.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/148\" class=\"nounderline abstract_t\">Rich-Edwards JW, Colditz GA, Stampfer MJ, et al. Birthweight and the risk for type 2 diabetes mellitus in adult women. Ann Intern Med 1999; 130:278.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/149\" class=\"nounderline abstract_t\">Whincup PH, Kaye SJ, Owen CG, et al. Birth weight and risk of type 2 diabetes: a systematic review. JAMA 2008; 300:2886.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/150\" class=\"nounderline abstract_t\">Dyck RF, Klomp H, Tan L. From &quot;thrifty genotype&quot; to &quot;hefty fetal phenotype&quot;: the relationship between high birthweight and diabetes in Saskatchewan Registered Indians. Can J Public Health 2001; 92:340.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/151\" class=\"nounderline abstract_t\">Harder T, Rodekamp E, Schellong K, et al. Birth weight and subsequent risk of type 2 diabetes: a meta-analysis. Am J Epidemiol 2007; 165:849.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/152\" class=\"nounderline abstract_t\">Sobngwi E, Boudou P, Mauvais-Jarvis F, et al. Effect of a diabetic environment in utero on predisposition to type 2 diabetes. Lancet 2003; 361:1861.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/153\" class=\"nounderline abstract_t\">Hofman PL, Regan F, Jackson WE, et al. Premature birth and later insulin resistance. N Engl J Med 2004; 351:2179.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/154\" class=\"nounderline abstract_t\">Wang G, Divall S, Radovick S, et al. Preterm birth and random plasma insulin levels at birth and in early childhood. JAMA 2014; 311:587.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/155\" class=\"nounderline abstract_t\">Hovi P, Andersson S, Eriksson JG, et al. Glucose regulation in young adults with very low birth weight. N Engl J Med 2007; 356:2053.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/156\" class=\"nounderline abstract_t\">Luna B, Feinglos MN. Drug-induced hyperglycemia. JAMA 2001; 286:1945.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/157\" class=\"nounderline abstract_t\">ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/158\" class=\"nounderline abstract_t\">Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95:29.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/159\" class=\"nounderline abstract_t\">Carlsen JE, K&oslash;ber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300:975.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/160\" class=\"nounderline abstract_t\">Passmore AP, Whitehead EM, Crawford V, et al. The antihypertensive and metabolic effects of low and conventional dose cyclopenthiazide in type II diabetics with hypertension. Q J Med 1991; 81:919.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/161\" class=\"nounderline abstract_t\">Harper R, Ennis CN, Heaney AP, et al. A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. Diabetologia 1995; 38:853.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/162\" class=\"nounderline abstract_t\">Helderman JH, Elahi D, Andersen DK, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1983; 32:106.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/163\" class=\"nounderline abstract_t\">Shafi T, Appel LJ, Miller ER 3rd, et al. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension 2008; 52:1022.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/164\" class=\"nounderline abstract_t\">Zillich AJ, Garg J, Basu S, et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006; 48:219.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/165\" class=\"nounderline abstract_t\">Lipscombe LL, L&eacute;vesque L, Gruneir A, et al. Antipsychotic drugs and hyperglycemia in older patients with diabetes. Arch Intern Med 2009; 169:1282.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/166\" class=\"nounderline abstract_t\">Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000; 157:975.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/167\" class=\"nounderline abstract_t\">Henderson DC. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psychiatry 2001; 62 Suppl 23:39.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/168\" class=\"nounderline abstract_t\">Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002; 63:920.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus/abstract/169\" class=\"nounderline abstract_t\">American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 1810 Version 23.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H40\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PATHOPHYSIOLOGY</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Impaired insulin secretion and insulin resistance</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">- Insulin secretion</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">- Insulin resistance</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">Impaired insulin processing</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Role of islet amyloid polypeptide</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">GENETIC SUSCEPTIBILITY</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">Pancreatic development and beta-cell function</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Insulin release</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">- Transcription factor genes</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">- MODY2 and MODY4</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">- Other</a></li></ul></li><li><a href=\"#H14\" id=\"outline-link-H14\">Insulin action</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Hepatocyte nuclear factors</a></li><li><a href=\"#H6585799\" id=\"outline-link-H6585799\">Other genes</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Animal models</a></li></ul></li><li><a href=\"#H17\" id=\"outline-link-H17\">ROLE OF DIET, OBESITY, AND INFLAMMATION</a><ul><li><a href=\"#H18\" id=\"outline-link-H18\">Free fatty acids</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Pattern of fat distribution</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">Factors released from adipose tissue</a><ul><li><a href=\"#H21\" id=\"outline-link-H21\">- Leptin</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">- Adiponectin</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">- Tumor necrosis factor-alpha</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">- Chemokine molecules</a></li><li><a href=\"#H25\" id=\"outline-link-H25\">- Plasminogen activator inhibitor</a></li><li><a href=\"#H26\" id=\"outline-link-H26\">- Resistin</a></li><li><a href=\"#H27\" id=\"outline-link-H27\">- Retinol-binding protein 4</a></li></ul></li><li><a href=\"#H28\" id=\"outline-link-H28\">Other factors</a><ul><li><a href=\"#H29\" id=\"outline-link-H29\">- Interleukin-1 beta</a></li><li><a href=\"#H30\" id=\"outline-link-H30\">- Uncoupling protein 2</a></li><li><a href=\"#H31\" id=\"outline-link-H31\">- Obestatin</a></li></ul></li></ul></li><li><a href=\"#H32\" id=\"outline-link-H32\">ROLE OF INTRAUTERINE DEVELOPMENT</a><ul><li><a href=\"#H33\" id=\"outline-link-H33\">Low birth weight</a></li><li><a href=\"#H34\" id=\"outline-link-H34\">High birth weight</a></li><li><a href=\"#H35\" id=\"outline-link-H35\">Prematurity</a></li></ul></li><li><a href=\"#H36\" id=\"outline-link-H36\">DRUG-INDUCED HYPERGLYCEMIA</a><ul><li><a href=\"#H37\" id=\"outline-link-H37\">Thiazide diuretics</a></li><li><a href=\"#H38\" id=\"outline-link-H38\">Antipsychotics</a></li></ul></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H39\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H40\" id=\"outline-link-H40\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ENDO/1810|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/51105\" class=\"graphic graphic_figure\">- Obesity and NIDDM</a></li><li><a href=\"image.htm?imageKey=ENDO/70645\" class=\"graphic graphic_figure\">- Obesity family hx and NIDDM</a></li><li><a href=\"image.htm?imageKey=ENDO/61582\" class=\"graphic graphic_figure\">- Genetic loci T2 DM</a></li><li><a href=\"image.htm?imageKey=ENDO/68962\" class=\"graphic graphic_figure\">- Glucose metabolism</a></li><li><a href=\"image.htm?imageKey=ENDO/79316\" class=\"graphic graphic_figure\">- Type2 DM weight and exercise</a></li><li><a href=\"image.htm?imageKey=ENDO/56394\" class=\"graphic graphic_figure\">- Fat distribution and NIDDM</a></li><li><a href=\"image.htm?imageKey=ENDO/52859\" class=\"graphic graphic_figure\">- Birth wt and insulin resistance</a></li><li><a href=\"image.htm?imageKey=NEPH/69912\" class=\"graphic graphic_figure\">- Thiazide side effects and dose</a></li></ul></li><li><div id=\"ENDO/1810|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/64684\" class=\"graphic graphic_table\">- Cand genes function T2 DM</a></li><li><a href=\"image.htm?imageKey=ENDO/67257\" class=\"graphic graphic_table\">- Drug induced diabetes</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=amylin-analogs-for-the-treatment-of-diabetes-mellitus\" class=\"medical medical_review\">Amylin analogs for the treatment of diabetes mellitus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=classification-of-diabetes-mellitus-and-genetic-diabetic-syndromes\" class=\"medical medical_review\">Classification of diabetes mellitus and genetic diabetic syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=genetic-contribution-and-pathophysiology-of-obesity\" class=\"medical medical_review\">Genetic contribution and pathophysiology of obesity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=genetics-of-congenital-and-acquired-long-qt-syndrome\" class=\"medical medical_review\">Genetics of congenital and acquired long QT syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ghrelin\" class=\"medical medical_review\">Ghrelin</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infant-of-a-diabetic-mother\" class=\"medical medical_review\">Infant of a diabetic mother</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lipodystrophic-syndromes\" class=\"medical medical_review\">Lipodystrophic syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=low-density-lipoprotein-cholesterol-lowering-with-drugs-other-than-statins-and-pcsk9-inhibitors\" class=\"medical medical_review\">Low density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=major-side-effects-of-inhaled-glucocorticoids\" class=\"medical medical_review\">Major side effects of inhaled glucocorticoids</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=major-side-effects-of-systemic-glucocorticoids\" class=\"medical medical_review\">Major side effects of systemic glucocorticoids</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-persistent-hyperglycemia-in-type-2-diabetes-mellitus\" class=\"medical medical_review\">Management of persistent hyperglycemia in type 2 diabetes mellitus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nutritional-considerations-in-type-2-diabetes-mellitus\" class=\"medical medical_review\">Nutritional considerations in type 2 diabetes mellitus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overweight-and-obesity-in-adults-health-consequences\" class=\"medical medical_review\">Overweight and obesity in adults: Health consequences</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diabetes-mellitus-type-2-overview-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Diabetes mellitus type 2: Overview (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=type-2-diabetes-the-basics\" class=\"medical medical_basics\">Patient education: Type 2 diabetes (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-cyclosporine-and-tacrolimus\" class=\"medical medical_review\">Pharmacology of cyclosporine and tacrolimus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=physiology-of-leptin\" class=\"medical medical_review\">Physiology of leptin</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=possible-role-of-low-birth-weight-in-the-pathogenesis-of-primary-essential-hypertension\" class=\"medical medical_review\">Possible role of low birth weight in the pathogenesis of primary (essential) hypertension</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-type-2-diabetes-mellitus\" class=\"medical medical_review\">Prevention of type 2 diabetes mellitus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=risk-factors-for-type-2-diabetes-mellitus\" class=\"medical medical_review\">Risk factors for type 2 diabetes mellitus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=risks-and-side-effects-associated-with-estrogen-progestin-contraceptives\" class=\"medical medical_review\">Risks and side effects associated with estrogen-progestin contraceptives</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=side-effects-of-androgen-deprivation-therapy\" class=\"medical medical_review\">Side effects of androgen deprivation therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=statins-actions-side-effects-and-administration\" class=\"medical medical_review\">Statins: Actions, side effects, and administration</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=structure-and-function-of-the-insulin-receptor\" class=\"medical medical_review\">Structure and function of the insulin receptor</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-metabolic-syndrome-insulin-resistance-syndrome-or-syndrome-x\" class=\"medical medical_review\">The metabolic syndrome (insulin resistance syndrome or syndrome X)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=thiazolidinediones-in-the-treatment-of-diabetes-mellitus\" class=\"medical medical_review\">Thiazolidinediones in the treatment of diabetes mellitus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-hypertension-in-patients-with-diabetes-mellitus\" class=\"medical medical_review\">Treatment of hypertension in patients with diabetes mellitus</a></li></ul></div></div>","javascript":null}